Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Sector: Medical
RDEA (NASDAQ: RDEA)
3m
6m
1y
2y
Ranking History
This Week
Last Week
Two Weeks Back
Three Weeks Back
Please login to view our current ranking data
Click here to login
No Information
No Information
No Information
Disclaimer
Headlines
Blog Articles
Premium News
Press Releases
SEC
Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
Nov 06, 2009 08:01 AM |
RDEA
Ardea Biosciences to Present at Three Upcoming Investor Conferences
Oct 28, 2009 08:30 AM |
RDEA
Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
Oct 19, 2009 07:30 AM |
RDEA
Ardea Biosciences to Present Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
Sep 30, 2009 08:30 AM |
RDEA
JMP Securities Healthcare Conference to Be Held in New York
Sep 29, 2009 05:30 PM |
ACAD
,
ALNY
,
ALTH
,
ALXA
,
ANDS
,
ATHN
Ardea Biosciences to Present at Three Upcoming Investor Conferences
Sep 16, 2009 08:30 AM |
BAC
,
RDEA
,
UBS
Ardea Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009
Aug 27, 2009 08:30 AM |
RDEA
Analyst Comments: Enzon Pharma, BHP Billiton, Lincoln Electric, Hologic, Ardea Biosciences, Gafisa, Buckeye Partners, Take-Two
Aug 18, 2008 02:55 PM |
BBL
,
BHP
,
BPL
,
ENZN
,
ERTS
,
GFA
Analyst Comments: Hospira, Ardea Biosciences, PepsiCo, ZION Bancorp, Procter & Gamble, Beacon Roofing, Amylin Pharmaceuticals, Double Eagle
Mar 25, 2008 06:39 PM |
AMLN
,
BECN
,
BIIB
,
CELG
,
DBLE
,
DNA
Analyst Comments: Zumiez, LSI Corporation, Chunghwa, Kinder Morgan Energy Partners, Kirkland
Dec 03, 2007 02:15 PM |
CHT
,
KIRK
,
KMP
,
LSI
,
RDEA
,
ZUMZ
More..
Gout cases increasing in United States
Jun 13, 2009 02:41 PM |
RDEA
More..
Ardea Biosciences Reports Recent Accomplishments and Announces Second Quarter and Year-to-Date 2009 Financial Results
Aug 07, 2009 08:32 AM |
RDEA
Ardea Biosciences Initiates Phase 2b Clinical Trial of RDEA594, Lead Product Candidate for the Treatment of Gout
Jul 20, 2009 08:14 AM |
RDEA
Ardea Biosciences to Present at the 4th Annual Piper Jaffray Europe Conference
Jun 18, 2009 08:36 AM |
RDEA
Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594
Jun 11, 2009 08:00 AM |
RDEA
Ardea Biosciences to Present Preclinical and Phase 1 Data on its Lead Gout Product Candidate, RDEA594, at the Annual European Congress of Rheumatology
May 18, 2009 08:51 AM |
RDEA
Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. Urge the Shareholders of Penwest Pharmaceuticals Co. To Vote for Their Shareholder Proposals
May 15, 2009 10:14 AM |
APPA
,
GENZ
,
NTII
,
PPCO
,
RDEA
Ardea Biosciences Reports Recent Accomplishments and First Quarter 2009 Financial Results
May 08, 2009 09:56 AM |
ONXX
,
RDEA
Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer
Apr 28, 2009 08:44 AM |
RDEA
Ardea Biosciences Announces Positive Results from a Phase 1 Study of Lead Hyperuricemia and Gout Candidate, RDEA594 and a Phase 2a Study of RDEA594’s Prodrug, RDEA806
Apr 20, 2009 04:04 PM |
RDEA
Ardea Biosciences Announces Investor and Analyst Event Participants and Webcast Information
Apr 13, 2009 08:37 AM |
RDEA
More..
Form 4 Quart Barry D For: Nov 09 (10K)
Nov 10, 2009 08:30 PM
Form 4 Ardea Biosciences, Inc./ For: Oct 23 Filed by: Krueger Christopher W (10K)
Oct 26, 2009 01:57 PM
Form 4 FUCHS HENRY J For: Oct 12 (10K)
Oct 14, 2009 01:13 PM
Form 4 Krueger Christopher W For: Sep 23 (10K)
Sep 24, 2009 01:44 PM
Form 4 FUCHS HENRY J For: Sep 10 (10K)
Sep 14, 2009 01:40 PM
Form 4 Krueger Christopher W For: Aug 24 (10K)
Aug 25, 2009 02:04 PM
Form 4 Beck John W For: Aug 14 (10K)
Aug 17, 2009 09:00 PM
Form 4 Quart Barry D For: Aug 11 (10K)
Aug 13, 2009 09:59 PM
Form 4 FUCHS HENRY J For: Aug 10 (10K)
Aug 12, 2009 01:49 PM
Form 4 Quart Barry D For: May 27 (10K)
May 29, 2009 01:47 PM
More..
Analyst Ratings
More Details
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
RDEA
Compare to S&P
YTD
14.29 %
-5.41 %
4 Weeks
-7.51 %
-8.50 %
12 Weeks
-23.83 %
-28.19 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
70.45 %
EPS Growth in Last Year:
86.32 %
Sales Growth in Last Quarter:
66.35 %
Sales Growth in Last Quarter:
-0.01 %
More...
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
